These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 11152097)

  • 1. Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors.
    Sheng-Tanner X; McKerlie C; Spaner D
    Transplantation; 2000 Dec; 70(12):1683-93. PubMed ID: 11152097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.
    Bhattacharyya S; Chawla A; Smith K; Zhou Y; Talib S; Wardwell B; Cowan MJ
    J Immunol; 2002 Dec; 169(11):6133-40. PubMed ID: 12444116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model.
    Yang YG; Dey B; Sergio JJ; Sykes M
    Transplantation; 1997 Nov; 64(9):1343-52. PubMed ID: 9371678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
    Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
    Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
    Schultz KR; Bader S; Paquet J; Li W
    Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
    Pan L; Delmonte J; Jalonen CK; Ferrara JL
    Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
    Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model.
    Friedman JS; Alpdogan O; van den Brink MR; Liu C; Hurwitz D; Boyd A; Kupper TS; Burakoff SJ
    Biol Blood Marrow Transplant; 2004 Jul; 10(7):448-60. PubMed ID: 15205666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term persistence of IL-2-unresponsive allogeneic T cells in sublethally irradiated SCID mice.
    Spaner D; Sheng-Tanner X; Raju K; Rabinovich B; Messner H; Miller RG
    Int Immunol; 1999 Oct; 11(10):1601-14. PubMed ID: 10508178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
    Martin PJ
    J Exp Med; 1993 Aug; 178(2):703-12. PubMed ID: 8101864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
    Shahin K; Mattar Z; Silveira P; Hsu WH; Bendall L; Hart D; Bradstock KF
    Transplantation; 2017 Nov; 101(11):2695-2704. PubMed ID: 28319565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.